{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16","upperLimit":"67","value":"41"},{"groupId":"OG001","lowerLimit":"17","upperLimit":"59","value":"37"},{"groupId":"OG002","lowerLimit":"52","upperLimit":"91","value":"68"},{"groupId":"OG003","lowerLimit":"63","upperLimit":"104","value":"78"},{"groupId":"OG004","lowerLimit":"28","upperLimit":"92","value":"55"},{"groupId":"OG005","lowerLimit":"34","upperLimit":"80","value":"58"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"description":"Percent Inhibition of pBAD at the C1D15 trough from the pBAD at pre-dose by ex vivo cellular assay","dispersionType":"Full Range","groups":[{"description":"INCB053914 will be self-administered orally once a day in as a 100mg immediate release tablet as a monotherapy.","id":"OG000","title":"Parts 1 and 2: INCB053914 100 mg QD"},{"description":"INCB053914 will be self-administered orally twice day in as a 50mg immediate release tablet as a monotherapy.","id":"OG001","title":"Parts 1 and 2: INCB053914 50 mg BID"},{"description":"INCB053914 will be self-administered orally twice day in as a 65mg immediate release tablet as a monotherapy.","id":"OG002","title":"Parts 1 and 2: INB053914 65 mg BID"},{"description":"INCB053914 will be self-administered orally twice day in as a 80mg immediate release tablet as a monotherapy.","id":"OG003","title":"Parts 1 and 2: INB053914 80 mg BID"},{"description":"INCB053914 will be self-administered orally twice day in as a 100mg immediate release tablet as a monotherapy.","id":"OG004","title":"Parts 1 and 2: INB053914 100 mg BID"},{"description":"INCB053914 will be self-administered orally twice day in as a 115mg immediate release tablet as a monotherapy.","id":"OG005","title":"Parts 1 and 2: INB053914 115 mg BID"}],"paramType":"MEAN","populationDescription":"The PD evaluable population includes those in the safety population who have at least 1 valid PD measurements at both pre- and postdose.","reportingStatus":"POSTED","timeFrame":"1 month","title":"Evaluation of Phosphorylated BCL--2 Associated Death Promoter Protein (pBAD)","type":"SECONDARY","unitOfMeasure":"Percentage of Inhibition"}